Recruitment ongoing in the phase II study (COMB study).

Recruitment of patients to the phase II study (COMB study) is ongoing at the clinical study site in Gothenburg and in Stockholm. The study team is sharing information about the study including [...]

Sobrera Pharma AB announces 28 MSEK capital raise through a directed share issue to finance the continued development of SO-001

Sobrera Pharma AB announces 28 MSEK capital raise through a directed share issue to finance the continued development of SO-001, a new oral therapy for patients with Alcohol Use Disorder (AUD). [...]